Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Fineline Cube Apr 16, 2026
Company Deals

Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment

Fineline Cube Apr 16, 2026
Company Deals

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development

Fineline Cube Apr 16, 2026
Company Deals

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235

Fineline Cube Apr 16, 2026
Company Deals

Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision

Fineline Cube Apr 16, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Fineline Cube Apr 16, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Fineline Cube Apr 16, 2026
Company

Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care

Fineline Cube Feb 6, 2025

Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached...

Company Drug

Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy

Fineline Cube Feb 6, 2025

Japan-based major Astellas Pharma (TYO: 4503) announced that it has submitted a New Drug Application...

Company Drug

Roche’s Susvimo Approved by FDA for Diabetic Macular Edema

Fineline Cube Feb 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG) announced that it has received approval from the US...

Company Drug

FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer

Fineline Cube Feb 6, 2025

The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody...

Company Deals

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study

Fineline Cube Feb 6, 2025

Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and...

Company Drug

Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study

Fineline Cube Feb 6, 2025

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...

Company Drug

Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Feb 6, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia

Fineline Cube Feb 6, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Deals

Henan Lingrui to Acquire Yingu Pharma for RMB 704 Million

Fineline Cube Feb 6, 2025

China’s Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285) announced plans to acquire a 90% ownership...

Company Drug

Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials

Fineline Cube Feb 6, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...

Company Drug

Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study

Fineline Cube Feb 6, 2025

China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the...

Company Deals

ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management

Fineline Cube Feb 6, 2025

China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into...

Company

Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Feb 6, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from...

Company Drug

Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378

Fineline Cube Feb 6, 2025

China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...

Company Deals

Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms

Fineline Cube Feb 5, 2025

China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...

Company Deals

Becton Dickinson Considers Spinning Off Life Sciences Division

Fineline Cube Feb 5, 2025

US-based Becton, Dickinson and Co. (BD) is reportedly considering spinning off its life sciences division,...

Company Deals

Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition

Fineline Cube Feb 5, 2025

Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone...

Company Deals

Nona Biosciences Partners with Invetx for Animal Health Therapies

Fineline Cube Feb 5, 2025

Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...

Company

AbbVie Reports Strong Q4 and Full-Year 2024 Financials

Fineline Cube Feb 5, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results,...

Company Drug

IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore

Fineline Cube Feb 5, 2025

China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...

Posts pagination

1 … 205 206 207 … 652

Recent updates

  • RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal
  • Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty
  • Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration
  • Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.